# PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)

> **NCT02747823** · PHASE1 · UNKNOWN · sponsor: **Cipla BioTec Pvt. Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** CBT124
- **BIOLOGICAL:** EU Sourced Avastin®
- **BIOLOGICAL:** US Sourced Avastin®

## Key facts

- **NCT ID:** NCT02747823
- **Lead sponsor:** Cipla BioTec Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2016-10
- **Final completion:** 2016-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2016-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02747823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02747823, "PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02747823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*